A prospective study to examine whether the 68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients with prostate cancer.

Trial Profile

A prospective study to examine whether the 68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients with prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms ProCan-I
  • Most Recent Events

    • 25 Dec 2015 New trial record
    • 18 Dec 2015 Results (n=70) published in the BJU International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top